Detalhe da pesquisa
1.
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
JAMA Oncol
; 7(12): 1772-1781, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647981
2.
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Nat Commun
; 12(1): 2487, 2021 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33941784
3.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov
; 9(2): 210-219, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425037